"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
Concept/Terms
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in Harvard Catalyst Profiles by year, and whether "Tumor Microenvironment" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 2 | 5 | 7 |
| 2011 | 8 | 21 | 29 |
| 2012 | 13 | 31 | 44 |
| 2013 | 14 | 30 | 44 |
| 2014 | 24 | 31 | 55 |
| 2015 | 38 | 33 | 71 |
| 2016 | 38 | 56 | 94 |
| 2017 | 37 | 70 | 107 |
| 2018 | 35 | 65 | 100 |
| 2019 | 60 | 115 | 175 |
| 2020 | 46 | 129 | 175 |
| 2021 | 54 | 154 | 208 |
| 2022 | 21 | 197 | 218 |
| 2023 | 1 | 45 | 46 |
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med. 2023 Mar; 29(3):632-645.
-
Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 2023 03 14; 7(5):718-733.
-
Polymerase ? inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nat Commun. 2023 Mar 13; 14(1):1390.
-
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Mol Cancer Ther. 2023 03 02; 22(3):406-418.
-
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha. Cancer Discov. 2023 03 01; 13(3):672-701.
-
The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. Mol Cancer Res. 2023 03 01; 21(3):253-260.
-
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer. 2023 03; 11(3).
-
Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 2023 02 28; 7(4):482-490.
-
Pleiotrophin drives a prometastatic immune niche in breast cancer. J Exp Med. 2023 May 01; 220(5).
-
Gene-based delivery of immune-activating cytokines for cancer treatment. Trends Mol Med. 2023 Apr; 29(4):329-342.